[go: up one dir, main page]

MX2018003173A - Vacunas de salmonella choleraesuis-salmonella typhimurium. - Google Patents

Vacunas de salmonella choleraesuis-salmonella typhimurium.

Info

Publication number
MX2018003173A
MX2018003173A MX2018003173A MX2018003173A MX2018003173A MX 2018003173 A MX2018003173 A MX 2018003173A MX 2018003173 A MX2018003173 A MX 2018003173A MX 2018003173 A MX2018003173 A MX 2018003173A MX 2018003173 A MX2018003173 A MX 2018003173A
Authority
MX
Mexico
Prior art keywords
salmonella
choleraesuis
typhimurium vaccines
vaccines
typhimurium
Prior art date
Application number
MX2018003173A
Other languages
English (en)
Inventor
James Fergen Brian
M Murphy Jordan Dianna
James KAISER Troy
Alan Smiley Rex
Original Assignee
Boehringer Ingelheim Vetmedica Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Vetmedica Inc filed Critical Boehringer Ingelheim Vetmedica Inc
Publication of MX2018003173A publication Critical patent/MX2018003173A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A61K39/0275—Salmonella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/542—Mucosal route oral/gastrointestinal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

La presente invención se refiere a métodos para reducir la diseminación fecal de animales infectados con Salmonella mediante el uso de una vacuna o composición inmunógena de Salmonella Choleraesuis-Typhimurium.
MX2018003173A 2015-09-16 2016-09-13 Vacunas de salmonella choleraesuis-salmonella typhimurium. MX2018003173A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562219271P 2015-09-16 2015-09-16
PCT/US2016/051448 WO2017048677A1 (en) 2015-09-16 2016-09-13 Salmonella choleraesuis-salmonella typhimurium vaccines

Publications (1)

Publication Number Publication Date
MX2018003173A true MX2018003173A (es) 2018-05-17

Family

ID=57068197

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018003173A MX2018003173A (es) 2015-09-16 2016-09-13 Vacunas de salmonella choleraesuis-salmonella typhimurium.

Country Status (6)

Country Link
US (1) US20170072042A1 (es)
JP (1) JP2018526454A (es)
AU (1) AU2016323106A1 (es)
CA (1) CA2996613A1 (es)
MX (1) MX2018003173A (es)
WO (1) WO2017048677A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10973908B1 (en) 2020-05-14 2021-04-13 David Gordon Bermudes Expression of SARS-CoV-2 spike protein receptor binding domain in attenuated salmonella as a vaccine
US12537071B1 (en) 2020-07-22 2026-01-27 David Gordon Bermudes Bacteria having boolean control pathways expressing therapeutic proteins including immunotherapeutic cytotoxins
WO2024245971A1 (en) * 2023-05-26 2024-12-05 Ceva Sante Animale Vaccine composition for use against salmonella choleraesuis infection

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US382425A (en) 1888-05-08 Brandt
US2909462A (en) 1955-12-08 1959-10-20 Bristol Myers Co Acrylic acid polymer laxative compositions
US3856935A (en) * 1971-04-29 1974-12-24 Schweiz Serum & Impfinst Oral typhoid vaccine and method of preparing the same
US4394448A (en) 1978-02-24 1983-07-19 Szoka Jr Francis C Method of inserting DNA into living cells
DE2843295A1 (de) * 1978-10-04 1980-10-30 Inst Impfstoffe Dessau Verfahren zur herstellung stabiler avirulenter und hochimmunogener bakterienmutanten fuer lebendimpfstoffe
US4769331A (en) 1981-09-16 1988-09-06 University Patents, Inc. Recombinant methods and materials
US5833975A (en) 1989-03-08 1998-11-10 Virogenetics Corporation Canarypox virus expressing cytokine and/or tumor-associated antigen DNA sequence
US5505941A (en) 1981-12-24 1996-04-09 Health Research, Inc. Recombinant avipox virus and method to induce an immune response
US5174993A (en) 1981-12-24 1992-12-29 Health Research Inc. Recombinant avipox virus and immunological use thereof
US4769330A (en) 1981-12-24 1988-09-06 Health Research, Incorporated Modified vaccinia virus and methods for making and using the same
US4722848A (en) 1982-12-08 1988-02-02 Health Research, Incorporated Method for immunizing animals with synthetically modified vaccinia virus
US5364773A (en) 1991-03-07 1994-11-15 Virogenetics Corporation Genetically engineered vaccine strain
US5338683A (en) 1981-12-24 1994-08-16 Health Research Incorporated Vaccinia virus containing DNA sequences encoding herpesvirus glycoproteins
US4603112A (en) 1981-12-24 1986-07-29 Health Research, Incorporated Modified vaccinia virus
US4745051A (en) 1983-05-27 1988-05-17 The Texas A&M University System Method for producing a recombinant baculovirus expression vector
US4945050A (en) 1984-11-13 1990-07-31 Cornell Research Foundation, Inc. Method for transporting substances into living cells and tissues and apparatus therefor
IL84154A0 (en) 1986-10-16 1988-03-31 Microgenesys Inc Polypeptides derived from the envelope gene of human immunodeficiency virus in recombinant baculovirus infected insect cells and vaccines against acquired immune deficiency syndrome containing the same
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
WO1990001543A1 (fr) 1988-07-29 1990-02-22 Intracel Corporation Procede d'expression genetique de proteines heterologues par des cellules transfectees in vivo
CA2003300A1 (en) 1988-11-21 1990-05-21 Franklin Volvovitz Skin test and test kit for aids
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
DK0737750T3 (da) 1989-03-21 2003-09-01 Vical Inc Ekspression af exogene polynucleotidsekvenser i vertebrater
US5591439A (en) 1989-03-24 1997-01-07 The Wistar Institute Of Anatomy And Biology Recombinant cytomegalovirus vaccine
US5552143A (en) 1989-03-24 1996-09-03 The Wistar Institute Of Anatomy & Biology Recombinant cytomegalovirus vaccine
GB9001766D0 (en) 1990-01-25 1990-03-28 Univ Court Of The University O Vaccines
EP0555366B1 (en) * 1990-11-01 2000-06-28 Iowa State University Research Foundation, Inc. Bacterial attenuation method and vaccine
EP0575491B1 (en) 1991-03-07 2003-08-13 Virogenetics Corporation Genetically engineered vaccine strain
US5997878A (en) 1991-03-07 1999-12-07 Connaught Laboratories Recombinant poxvirus-cytomegalovirus, compositions and uses
US5580557A (en) * 1991-10-09 1996-12-03 Iowa State University Research Foundation, Inc. Live, avirulent salmonella choleraesuis vaccine used for inducing an immune response in animals
US5643578A (en) 1992-03-23 1997-07-01 University Of Massachusetts Medical Center Immunization by inoculation of DNA transcription unit
US5801029A (en) 1993-02-16 1998-09-01 Onyx Pharmaceuticals, Inc. Cytopathic viruses for therapy and prophylaxis of neoplasia
IL108915A0 (en) 1993-03-18 1994-06-24 Merck & Co Inc Polynucleotide vaccine against influenza virus
FR2711670B1 (fr) 1993-10-22 1996-01-12 Pasteur Institut Vecteur nucléotidique, composition le contenant et vaccin pour l'immunisation à l'encontre d'une hépatite.
EP1170368B1 (en) 1994-01-27 2010-07-28 University Of Massachusetts Medical Center Immunization by inoculation of dna transcription unit
WO1995030018A2 (en) 1994-04-29 1995-11-09 Immuno Aktiengesellschaft Recombinant poxviruses with foreign polynucleotides in essential regions
CA2215162A1 (en) 1995-03-23 1996-09-26 Cantab Pharmaceuticals Research Limited Vectors for gene delivery
EP0979101B1 (en) 1996-07-03 2010-10-27 Merial, Inc. Recombinant canine adenovirus 2 (cav2) containing exogenous dna
US6183752B1 (en) 1997-02-05 2001-02-06 Pasteur Merieux Serums Et Vaccins Restenosis/atherosclerosis diagnosis, prophylaxis and therapy
US6656478B1 (en) * 1999-11-12 2003-12-02 Samuel D. Charles Cross-protective salmonella vaccines
NZ521425A (en) * 2000-03-17 2004-05-28 Upjohn Co Vaccine comprising a first attenuated non-reverting mutant Salmonella in which two or more secretion system apparatus genes have been inactivated
RU2162340C1 (ru) * 2000-04-17 2001-01-27 Всероссийский научно-исследовательский институт защиты животных Способ изготовления вакцины против сальмонеллеза свиней
RU2470663C1 (ru) * 2011-09-19 2012-12-27 Государственное научное учреждение Всероссийский научно-исследовательский институт экспериментальной ветеринарии им. Я.Р. Коваленко (ВИЭВ) Вакцина против сальмонеллеза свиней, способ изготовления, способ профилактики сальмонеллеза свиней

Also Published As

Publication number Publication date
WO2017048677A1 (en) 2017-03-23
AU2016323106A9 (en) 2019-08-01
WO2017048677A9 (en) 2018-03-08
US20170072042A1 (en) 2017-03-16
AU2016323106A1 (en) 2018-03-29
JP2018526454A (ja) 2018-09-13
CA2996613A1 (en) 2017-03-23

Similar Documents

Publication Publication Date Title
IL272306B (en) Pridopidine analogues, their preparation and use
PT3718565T (pt) Vacinas contra vírus respiratórios
AP2016009664A0 (en) Attenuated african swine fever virus vaccine
LT3218504T (lt) Trijų segmentų arenavirusai kaip vakcinos vektoriai
SG11202010821TA (en) Vaccine composition
HRP20181895T1 (hr) Terapijska hpv16 cjepiva
SG11201609062PA (en) Adenoviral vector-based vaccine against enterovirus infection
IL263550A (en) Infectious bronchitis virus vaccine
ZA201608487B (en) Dual adjuvant vaccine compositions, preparation and uses
GB201617324D0 (en) Vaccine compositions
MX2018003173A (es) Vacunas de salmonella choleraesuis-salmonella typhimurium.
ZA202204980B (en) Vaccine against infectious bronchitis
GB201703529D0 (en) Vaccine composition
GB201811382D0 (en) Vaccine
GB201803787D0 (en) Oncolytic viruses as adjuvants
GB201807376D0 (en) HMCV Vaccine Composition
GB201807378D0 (en) Vaccine composition
GB201807303D0 (en) Glyconjugate vaccines
GB201712904D0 (en) Vaccine
GB201704892D0 (en) Improved vaccines
GB201704126D0 (en) Vaccine
GB201703809D0 (en) Vaccine
GB201707785D0 (en) Vaccination
GB201706798D0 (en) Vaccination
TH1501001330A (th) องค์ประกอบของวัคซีนเชื้อเป็นแบบผสมสำหรับป้องกันโรคสเตรปโตคอคโคซีส ในสัตว์น้ำและกรรมวิธีการผลิตองค์ประกอบของวัคซีนดังกล่าว